With the introduction of new therapeutic options, the landscape of metastatic bladder cancer (mBC) management is shifting. We describe current clinical practice and outcomes of mBC patients as a benchmark for translation of developments into clinical practice in the near future.
To explore the immunohistochemistry-based molecular subtypes of bladder cancer, and their impact on the prognosis and the chemotherapy response between gemcitabine plus cisplatin intra-arterial chemotherapy and epirubicin-inducted intravesical chemotherapy, in patients with T1 stage bladder cancer after bladder-preserving treatment.
To evaluate the effect of second transurethral resection (TUR) on oncological outcomes, according to the presence or absence of detrusor muscle in the initial TUR of patients with pTa Grade 3 / high grade (G3/HG) tumors, who received at least 1 year of maintenance Bacillus Calmette-Guerin (BCG) therapy.
Prostate cancer generally has a very good prognosis with a five-year survival of 98%. However, a subset of men will develop recurrence and metastatic castration-resistant prostate cancer (mCRPC), and occasionally metastatic disease which is resistant to androgen deprivation therapy (ADT). The prognosis of patients with distant metastatic disease is far worse, with a five-year survival […]
While interstitial cystitis/bladder pain syndrome (IC/BPS) has previously been thought to be a disease of young women, recent studies indicate that IC/BPS occurs across all age groups; with one study reporting 38% of patients with IC/BPS being diagnosed at an age greater than 60 years.1 Older patients with IC/BPS may present with different symptoms than […]
Immune checkpoint inhibitors (CPIs) were recently approved in advanced clear cell renal cell carcinoma (RCC) and could be a promising option for metastatic RCC with sarcomatoid differentiation (sRCC) which otherwise carry a poor prognosis.
Papillary renal cell carcinoma type 2 (PRCC2) is refractory to systemic treatment and has a dismal prognosis. Previous studies showed that genetic alterations in PRCC2 were heterogeneous regardless of germline or somatic mutations.
To compare overall survival between patients with metastatic renal cell carcinoma treated by cytoreductive nephrectomy and those not treated by cytoreductive nephrectomy. We retrospectively evaluated 278 patients with metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitors between January 2008 and November 2019.
Prostate cancer ranks among the top 5 cancers in contribution to national expenditures. Previous reports have identified that 5% of the population accounts for 50% of the nation’s annual health care spending.
Altered lipid metabolism and subsequent changes in cellular lipid composition have been observed in prostate cancer cells, are associated with poor clinical outcome, and are promising targets for metabolic therapies.
